Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Vimab Group AB is a company primarily involved in the industrial services sector, focusing on providing specialized solutions across various engineering domains. The company's primary function is to offer services such as inspection, maintenance, and engineering design targeted at industries like petrochemical, energy, and manufacturing. Vimab Group AB is known for its expertise in non-destructive testing (NDT) and other maintenance services that ensure safety and efficiency in industrial operations. By serving critical sectors, Vimab Group AB plays a significant role in maintaining industry standards and operational safety, which are crucial for minimizing downtime and maximizing the lifespan of industrial equipment and structures. Its contributions are vital in quality assurance processes that help clients adhere to stringent regulatory requirements and environmental standards. Vimab Group AB operates out of Sweden, emphasizing precision and reliability in its service offerings. Through technological innovation and skilled workforce deployment, the company enhances its market position as a trusted leader in industrial service solutions.
kr 0.23
+kr 0.00 (+0.00%)
EOD Jun 26, 2026 · Twelve Data
The business is unprofitable at the operating level (-20.74% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue declined 3.1% YoY. The question is whether this is cyclical or a structural shift.
ROIC dropped from -42.97% to -59.70%, capital efficiency is deteriorating. Negative free cash flow of -kr 28M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
kr 326M
▼ -3.1% YoY
Net Income (TTM)
-kr 93M
▼ -19.9% YoY
Op. Margin
-21.77%
▲ +3.8pp YoY
ROIC
-59.70%
▼ -16.7pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-kr 56M
▼ -245.1% YoY
Op. Cash Flow (TTM)
-kr 6M
▼ -288.3% YoY
Net Debt
-kr 3M
Net Cash Position
Cash & Equiv.
kr 37M
3Y CAGR: +11.7%
Continue Research
Vimab Group AB (VIMAB.XSTO)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Vimab Group AB scores 21/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Vimab Group AB scores 21 out of 100 on Intrinsiqq's quality score, a weighted blend of 6 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -21.8% operating margin and a -59.7% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh VIMAB.XSTO's valuation and scores 21/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.